In addition, vvDD-nsmDR-18 treatment was associated with expansion of CD39<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> tumor-reactive T cells and a shift toward a lower PD-1 expression phenotype within this population. This evidence concerns the gene ENTPD1 and neoplasm.